12th August 2019
I lived in the US for a couple of years. Enjoyed it enormously. Most things were familiar, a common language tends to do that, but it took a few months to get used to the ADHD television. Cutting from a restaurant scene to an advertisement for a Ford town car, seamlessly, was a little uncomfortable. I lost the plot a couple of times. Sixteen years later, after working in Switzerland and Germany, back in the UK I see this is now common practice here too.
The human brain does not handle severa ...
Read full article
5th December 2017
I was thinking back to the time when I had my first performance appraisal. It was an uncomfortable experience. I armed myself with justifications for a good review, including as many examples of my performance as I could find. The whole discussion was a jousting match between me and my manger. He tried to convince me that I was average, while I tried to show him that my actions had resulted in great progress for my brands, so I should be rated as excellent. I lost.
I recall that the appraisa ...
Read full article
17th November 2017
Pharmaceutical companies, bound up by regulations and constraints, sometimes struggle to engage with the group that matter most – patients. My recent attendance at the Cambridge Rare Disease Network (CRDN) congress reminded me that patient engagement is simpler than we think. The congress gave me insight into how our agency can help big pharma become better at engaging with patients who have rare diseases.
On Monday 26th October at Robinson College, we set up our stand among 200 people ...
Read full article